Approximately 25% of patients with metastatic castration resistant prostate cancer
(mCRPC) have sporadic homologous recombination deficiency (HRD) mutations, with 8%
being germline mutations.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med. 2011; 364: 1995-2005
- Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med. 2012; 367: 1187-1197
- Integrative clinical genomics of advanced prostate cancer.Cell. 2015; 161: 1215-1228
- Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol. 2013; 31: 1748-1757
- DNA-repair defects and olaparib in metastatic prostate cancer.N Engl J Med. 2015; 373: 1697-1708
- The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Cancer. 2017; 123: 3532-3539
- DNA interstrand crosslink repair and cancer.Nat Rev Cancer. 2011; 11: 467-480
- Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).Ann Oncol. 2018; 29: 654-660
- Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.Anticancer Res. 2010; 30: 4317-4323
- Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.Clin Genitourin Cancer. 2014; 12: e197-e203
- Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.Med Oncol. 2015; 32: 443
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.J Clin Oncol. 2008; 26: 1148-1159
- PROfound: a randomized phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.J Clin Oncol. 2017; 35: TPS5091
- 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.Lancet Oncol. 2013; 14: 117-124
- Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.Med Oncol. 2013; 30: 717
- Prostate cancer heterogeneity: discovering novel molecular targets for therapy.Cancer Treat Rev. 2017; 54: 68-73
- Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.N Engl J Med. 2017; 377: 523-533
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med. 2012; 366: 1382-1392
- Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.J Urol. 2007; 177 (discussion: 2140): 2136-2140
- Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.Cancer Treat Rev. 2011; 37: 444-455
- Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.Br J Cancer. 2012; 106: 1464-1465
- Oral cyclophosphamide for the management of hormone-refractory prostate cancer.Br J Urol. 1993; 72: 625-628
- Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.Med Oncol. 2010; 27: 363-367
- Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.Jpn J Clin Oncol. 2011; 41: 253-259
- Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.Urology. 2011; 78: 1125-1130
- Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.J Cancer Res Clin Oncol. 2012; 138: 333-339
- Phase 2 study of cyclophosphamide, etoposide, and estramustine in patients with castration-resistant prostate cancer.Clin Genitourin Cancer. 2018; 16: 473-481
- Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.Eur Urol. 2016; 69: 992-995
- Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer.Cell. 2018; 173: 1770-1782.e14
Article info
Publication history
Published online: December 18, 2018
Accepted:
December 7,
2018
Received in revised form:
December 5,
2018
Received:
October 29,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
